for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

60.55USD

Change

-0.02(-0.03%)

Volume

9,174,009

Today's Range

59.85

 - 

60.90

52 Week Range

59.85

 - 

85.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
60.57
Open
60.59
Volume
9,174,009
3M AVG Volume
192.40
Today's High
60.90
Today's Low
59.85
52 Week High
85.97
52 Week Low
59.85
Shares Out (MIL)
1,253.72
Market Cap (MIL)
75,938.09
Forward P/E
8.91
Dividend (Yield %)
4.49

Next Event

Q3 2020 Gilead Sciences Inc Earnings Release

Latest Developments

更多

FDA Says Remdesivir EUA Letter Of Authorization, Reissued Oct 16

European CHMP Adopts Positive Opinion For Kite's KTE-X19 For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma

Gilead Sciences Issues Statement On Solidarity Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer, Executive Vice President

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Jyoti Mehra

Executive Vice President of Human Resources

Linda Higgins

Senior Vice President - Head of External Innovation

Key Stats

2.48 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

26.1K

2018

22.1K

2019

22.4K

2020(E)

24.2K
EPS (USD)

2017

8.840

2018

6.670

2019

6.630

2020(E)

6.988
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.42
Price To Book (MRQ)
4.21
Price To Cash Flow (TTM)
68.47
Total Debt To Equity (MRQ)
133.70
LT Debt To Equity (MRQ)
117.06
Return on Investment (TTM)
-0.58
Return on Equity (TTM)
-0.48

Latest News

Latest News

UPDATE 2-EU urged to review remdesivir supply deal after COVID-19 trial results

The European Union should renegotiate a 1 billion euro ($1.2 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.

UPDATE 2-Row breaks out over WHO trial casting doubt on remdesivir as COVID-19 drug

* Independent statistician says it's a "reliable result" (Adds details throughout, comments from experts)

WHO defends data after concluding Gilead's remdesivir flopped COVID trial

A World Health Organization (WHO) trial that concluded Gilead Sciences Inc. remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated it said on Friday, as the U.S. company criticized its methodology.

UPDATE 3-Gilead questions WHO study that cast doubts on drug's COVID-19 benefits

* Solidarity trial included more than 11,000 patients (Recasts with Gilead Sciences Inc's reaction)

WHO study says remdesivir did not reduce mortality in COVID-19 patients - FT

Gilead Sciences Inc's remdesivir had no substantial effect on COVID-19 patients' chances of survival, a clinical trial by the World Health Organization (WHO) has found, the Financial Times reported on Thursday.

UPDATE 1-EU makes 1 bln-euro bet on Gilead's COVID drug before trial results

The European Union has agreed to pay more than 1 billion euros ($1.2 billion) to Gilead for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication.

NIH starts clinical trial testing antibody treatments in COVID-19 patients

The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency's program to identify promising drugs to help tackle the new coronavirus.

UPDATE 1-Gilead's remdesivir shaved 5 days off COVID-19 recovery time, reduced risk of death in some

Final data from Gilead Sciences Inc's antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said on Thursday.

Gilead's remdesivir shaved 5 days off COVID-19 recovery time, reduced risk of death in some

Final data from Gilead Sciences Inc's antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than previously reported preliminary data showed, the company and researchers said on Thursday...

Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial, data shows

Eli Lilly and Co said on Thursday fewer deaths were reported among COVID-19 patients taking a combination of its rheumatoid arthritis drug and Gilead Sciences Inc's remdesivir in a clinical trial, compared to only remdesivir.

REFILE-UPDATE 2-Europe stocks up on Gilead's remdesivir as COVID-19 infections spike

Gilead Sciences said on Thursday it had agreed to sell Europe up to 500,000 courses of its antiviral drug remdesivir, as the continent shores up supplies of one of only two drugs approved to treat COVID-19 patients ahead of the winter.

UPDATE 1-European countries face shortages of COVID-19 drug remdesivir

* Europe eyes new supply deal with Gilead shortly (Updates situation in Spain in paragraph 8)

European countries face shortages of COVID-19 drug remdesivir

European countries are facing shortages of COVID-19 drug remdesivir because limited supplies are running out, officials said, with cases surging and the United States having bought up most of drugmaker Gilead's output.

EMA committee probes possible kidney injury from Gilead's remdesivir

The European drugs regulator said on Friday its safety committee was reviewing reports of acute kidney injury in some COVID-19 patients who had been given Gilead Sciences Inc's remdesivir.

HHS says Gilead, distributor can directly sell COVID-19 drug in U.S.

The U.S. Department of Health and Human Services (HHS) said on Thursday that U.S. hospitals can now buy Gilead Sciences Inc's antiviral COVID-19 drug remdesivir from the company and its distributor.

UPDATE 2-Gilead to pay $97 million to settle U.S. kickback probe

Gilead Sciences Inc has agreed to pay $97 million to resolve U.S. government claims it used a purportedly independent charity to pay illegal kickbacks to cover Medicare patients' out-of-pocket costs for its pulmonary arterial hypertension drug Letairis.

UPDATE 1-Immunomedics' cancer drug helps reduce tumor size in early-stage study

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Immunomedics reports promising early-stage data from cancer drug study

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

UPDATE 2-Gilead bolsters cancer portfolio with $21 bln acquisition of Immunomedics

* Trodelvy targets elusive and aggressive type of breast cancer

Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients

Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up